NCT05754450

An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II

A Phase 3, Open-Label, Extension Study to Assess the Long-term Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II)

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2 (estimated)
• Sponsor: AUG Therapeutics · Industry
• Sex: All
• Age: 6 Months – 75 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).

Conditions

• Leukocyte Adhesion Deficiency

Interventions

Type	Name	Description
DRUG	AVTX-803	L-fucose crystalline powder

Timeline

• Start date: 2023-04-10
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2023-03-03
• Last updated: 2024-11-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study